• Corpus ID: 207800909

HCRP1, ID4 and Glypican-3: an optimal panel of biomarkers for diagnosis of hepatocellular carcinoma.

  title={HCRP1, ID4 and Glypican-3: an optimal panel of biomarkers for diagnosis of hepatocellular carcinoma.},
  author={Shujian Ge and Dan Wang and Beibei Lv and Shuping Yang and Chunmei Liu and Bin Xu and Chunming Zhao and Ye-jun Qin and Jiawen Xu},
  journal={International journal of clinical and experimental pathology},
  volume={11 12},
BACKGROUND Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with high morbidity and mortality. The aim of this study was to assess the diagnostic role of HCC related protein 1 (HCRP1) and inhibitor of DNA Binding 4 (ID4) as novel reliable markers for HCC diagnosis. METHODS Immunohistochemistry for HCRP1, ID4 and Glypican-3 (GPC-3) was performed in 98 cases of HCCs, 15 large regenerative nodules arising in cirrhotic livers, 12 hepatocellular adenomas (HCA), 10… 
1 Citations

Figures and Tables from this paper

Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis.
An affinity exosome capture assay was developed that specifically captures GPC3 positive exosomes in the serum and shows that GPC 3 positiveExosomes can be used for HCC detection and prediction of treatment outcomes.


Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
The results of this study suggest that GPC3 is a biomarker that is sensitive and specific to HCC component of CHC, and CK7 and CK19 are markers for pathological cholangiocarcinoma component ofCHC.
HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer.
Low HCRP1 expression was found to be of adverse prognostic significance in patients with OOSCC who received preoperative chemoradiotherapy, and remained an independent risk factor for relapse and death.
Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer
The development of immunotoxins provides opportunities for novel liver cancer therapies, and three high affinity antibodies have demonstrated the ability to inhibit Wnt/Yap signaling, leading to a reduction in liver cancer cell proliferation.
Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity
It was concluded that HSP70, GPC3 and GS expressions could be useful biomarkers for increasing the specificity and sensitivity of HCC diagnosis to acceptable level and proper combinations of these 3 markers could improve diagnostic accuracy.
Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients.
It is suggested that HCRP1 may play an important role in EGFR regulation and that its decreased expression is an independent predictor of breast cancer, especially in TNBC patients.
HCRP1, a novel gene that is downregulated in hepatocellular carcinoma, encodes a growth-inhibitory protein.
Id4 promotes cell proliferation in hepatocellular carcinoma
It is found that the expression of Id4 protein was up-regulated in tumor tissues from HCC patients, suggesting that Id4 may be developed as a potent therapeutic agent for the treatment of HCC.
HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance
It is demonstrated that HCRP1 is downregulated in NSCLC and regulates proliferation, invasion, and drug resistance through modulation of EGFR signaling.
HCRP1 inhibits TGF-β induced epithelial-mesenchymal transition in hepatocellular carcinoma.
A novel function for HCRP1 is defined from the perspective of EMT, which is closely associated with the migration and invasion of HCC cells and induced epithelial-mesenchymal transition (EMT) through the transforming growth factor-β pathway.
Waiting-time and quality of care deserved to patients with early stage hepatocellular carcinoma undergoing RFA treatment
The authors propose to evaluate whether wait times for RFA were associated with residual tumor, tumor recurrence, need for liver transplantation, or death, and analyze this issue by using Radio Frequency Ablation (RFA) therapy, which actually represents one of the most widespread ablative methods in the world, having replaced the alcoholization technique, in most liver tumors.